Compare MTDR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTDR | XENE |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.2B |
| IPO Year | 2011 | 2014 |
| Metric | MTDR | XENE |
|---|---|---|
| Price | $52.81 | $67.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $63.07 | ★ $68.55 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,696,277,000.00 | $311,000.00 |
| Revenue This Year | $7.15 | N/A |
| Revenue Next Year | $7.63 | $2,496.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.46 | N/A |
| 52 Week Low | $37.14 | $30.00 |
| 52 Week High | $66.84 | $72.66 |
| Indicator | MTDR | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 69.54 |
| Support Level | $52.34 | $52.40 |
| Resistance Level | $57.65 | N/A |
| Average True Range (ATR) | 1.45 | 2.70 |
| MACD | 0.53 | 0.72 |
| Stochastic Oscillator | 76.15 | 67.89 |
Matador Resources Co is an independent energy company engaged in the exploration, development, production, and acquisition of oil and natural gas resources. The majority of the company's assets are located in the United States, with an emphasis on oil and natural gas shale and other unconventional plays. Along with maintaining a portfolio of oil and natural gas properties, Matador works to identify and develop midstream opportunities that support and enhance its exploration and development business. The Company has two reportable business segments: exploration and production and midstream. The company generates majority of its revenue from the exploration and production segment.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.